Merlin L Robb

List of Publications by Year
in descending order

173 papers	14,880 citations	41344 49 h-index	19749 117 g-index
181 all docs	181 docs citations	181 times ranked	10747 citing authors

#	Article	IF	Citations
1	Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New England Journal of Medicine, 2009, 361, 2209-2220.	27.0	2,748
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	27.0	1,699
3	Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. Journal of Virology, 1999, 73, 4009-4018.	3.4	725
4	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature, 2014, 512, 74-77.	27.8	527
5	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 2012, 482, 89-93.	27.8	452
6	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature, 2012, 490, 417-420.	27.8	405
7	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. Cell, 2013, 155, 531-539.	28.9	334
8	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. Journal of Infectious Diseases, 2012, 206, 431-441.	4.0	273
9	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
10	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nature Medicine, 2018, 24, 923-926.	30.7	263
11	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature, 2016, 540, 284-287.	27.8	246
12	COMPASS identifies T-cell subsets correlated with clinical outcomes. Nature Biotechnology, 2015, 33, 610-616.	17.5	232
13	Effect of Human Immunodeficiency Virus Type 1 (HIVâ€1) Subtype on Disease Progression in Persons from Rakai, Uganda, with Incident HIVâ€1 Infection. Journal of Infectious Diseases, 2008, 197, 707-713.	4.0	230
14	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. New England Journal of Medicine, 2016, 374, 2120-2130.	27.0	229
15	Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. PLoS Pathogens, 2014, 10, e1004543.	4.7	218
16	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e75665.	2.5	214
17	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infectious Diseases, The, 2012, 12, 531-537.	9.1	201
18	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Clinical Infectious Diseases, 2017, 64, 124-131.	5.8	200

#	Article	IF	Citations
19	HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine, 2016, 11, 68-72.	6.1	193
20	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses, 2012, 28, 1444-1457.	1.1	191
21	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology, 2014, 88, 7715-7726.	3.4	169
22	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
23	Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€"report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	4.7	139
24	Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. Clinical Infectious Diseases, 2016, 63, 555-561.	5.8	104
25	Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. Immunity, 2016, 44, 167-178.	14.3	104
26	Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. Aids, 2002, 16, 1809-1820.	2.2	99
27	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation, 2014, 124, 3879-3890.	8.2	99
28	Delayed differentiation of potent effector CD8 ⁺ T cells reducing viremia and reservoir seeding in acute HIV infection. Science Translational Medicine, 2017, 9, .	12.4	95
29	Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology, 2008, 375, 529-538.	2.4	88
30	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV,the, 2018, 5, e366-e378.	4.7	86
31	Among 46 Near Full Length HIV Type 1 Genome Sequences from Rakai District, Uganda, Subtype D and AD Recombinants Predominate. AIDS Research and Human Retroviruses, 2002, 18, 1281-1290.	1.1	82
32	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity, 2019, 50, 677-691.e13.	14.3	77
33	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of Virus Eradication, 2016, 2, 43-48.	0.5	73
34	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73
35	Accelerating Development of SARS-CoV-2 Vaccines â€" The Role for Controlled Human Infection Models. New England Journal of Medicine, 2020, 383, e63.	27.0	73
36	The Changing Molecular Epidemiology of HIV Type 1 among Northern Thai Drug Users, 1999 to 2002. AIDS Research and Human Retroviruses, 2004, 20, 465-475.	1.1	72

#	Article	IF	Citations
37	Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia. Journal of Virology, 2015, 89, 7494-7505.	3.4	70
38	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. Science Translational Medicine, 2020, 12, .	12.4	69
39	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Journal of Virology, 2016, 90, 1321-1332.	3.4	68
40	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathogens, 2017, 13, e1006510.	4.7	63
41	Primeâ€"boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Review of Vaccines, 2010, 9, 1055-1069.	4.4	62
42	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nature Medicine, 2020, 26, 228-235.	30.7	61
43	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV,the, 2020, 7, e688-e698.	4.7	58
44	Failure of the Merck HIV vaccine: an uncertain step forward. Lancet, The, 2008, 372, 1857-1858.	13.7	57
45	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
46	Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. Journal of Infectious Diseases, 2013, 207, 1195-1205.	4.0	56
47	Impact of early cART in the gut during acute HIV infection. JCI Insight, 2016, 1, .	5.0	56
48	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine, 2014, 1, 37-45.	6.1	55
49	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. Journal of Virology, 2014, 88, 8242-8255.	3.4	55
50	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS ONE, 2017, 12, e0180720.	2.5	55
51	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. Journal of Clinical Investigation, 2019, 129, 3361-3373.	8.2	54
52	Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology, 2008, 376, 101-111.	2.4	51
53	Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine, 2009, 27, 5885-5895.	3.8	51
54	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. PLoS Computational Biology, 2015, 11, e1003973.	3.2	51

#	Article	IF	Citations
55	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nature Medicine, 2015, 21, 1139-1141.	30.7	50
56	Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13439-13444.	7.1	49
57	Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok. Journal of the International AIDS Society, 2017, 20, 21708.	3.0	48
58	HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. Aids, 2005, 19, 1517-1524.	2.2	47
59	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Science Translational Medicine, 2015, 7, 296ra112.	12.4	47
60	Lessons from acute HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 555-560.	3.8	47
61	Distinguishing molecular forms of HIV-1 in Asia with a high-throughput, fluorescent genotyping assay, MHAbce v.2. Virology, 2007, 358, 178-191.	2.4	46
62	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
63	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Science Translational Medicine, 2019, 11, .	12.4	46
64	A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. ELife, 2016, 5, .	6.0	46
65	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. Journal of Virology, 2018, 92, .	3.4	45
66	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of Virus Eradication, 2016, 2, 43-48.	0.5	45
67	Higher HIV-1 Incidence and Genetic Complexity Along Main Roads in Rakai District, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 440-445.	2.1	44
68	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. Nature Communications, 2018, 9, 1212.	12.8	44
69	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e737-e749.	4.7	43
70	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 2020, 26, 498-501.	30.7	43
71	Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma. Journal of Infectious Diseases, 2019, 220, 1885-1891.	4.0	42
72	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Research and Human Retroviruses, 2017, 33, 410-423.	1.1	38

#	Article	IF	Citations
73	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. Nature Communications, 2020, 11, 272.	12.8	38
74	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
75	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathogens, 2020, 16, e1008764.	4.7	37
76	Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans. PLoS ONE, 2011, 6, e18779.	2.5	36
77	Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. PLoS Pathogens, 2016, 12, e1005805.	4.7	36
78	Phase I Study of Safety and Immunogenicity of an Escherichia coli-Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults. PLoS ONE, 2010, 5, e13849.	2.5	35
79	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	4.0	35
80	Structural and functional brain imaging in acute HIV. NeuroImage: Clinical, 2018, 20, 327-335.	2.7	34
81	Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. Journal of Virology, 2015, 89, 7478-7493.	3.4	33
82	Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16â€“STINGâ€“Type I IFN Pathway and AIM2 Sensor. Journal of Immunology, 2017, 199, 3293-3305.	0.8	33
83	Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	33
84	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV,the, 2020, 7, e238-e248.	4.7	33
85	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathogens, 2021, 17, e1009339.	4.7	32
86	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 108-117.	2.1	31
87	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. Journal of Clinical Investigation, 2020, 130, 2845-2858.	8.2	31
88	HIV-1 vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 1734-1746.	3.3	30
89	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathogens, 2018, 14, e1006973.	4.7	30
90	Prospects for a Globally Effective HIV-1 Vaccine. American Journal of Preventive Medicine, 2015, 49, S307-S318.	3.0	29

#	Article	IF	Citations
91	Prospects for a globally effective HIV-1 vaccine. Vaccine, 2015, 33, D4-D12.	3.8	28
92	Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. Journal of Infectious Diseases, 2018, 218, 1453-1463.	4.0	28
93	Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1. AIDS Research and Human Retroviruses, 2003, 19, 807-816.	1.1	27
94	Evolution of HIV-1 within untreated individuals and at the population scale in Uganda. PLoS Pathogens, 2018, 14, e1007167.	4.7	27
95	Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 2014, 11, 78.	2.0	26
96	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. Science Translational Medicine, 2019, 11, .	12.4	26
97	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathogens, 2018, 14, e1006888.	4.7	26
98	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. Journal of Virology, 2016, 90, 4005-4016.	3.4	25
99	Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLoS ONE, 2018, 13, e0206838.	2.5	25
100	Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. PLoS Pathogens, 2016, 12, e1005663.	4.7	25
101	Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection. Journal of Clinical Microbiology, 2019, 57, .	3.9	24
102	Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. PLoS Pathogens, 2020, 16, e1008179.	4.7	24
103	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. Journal of Clinical Investigation, 2020, 130, 3299-3304.	8.2	24
104	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0136626.	2.5	23
105	Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7Râˆ' Transcriptional Signature Express FcÎ³RIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. Journal of Immunology, 2019, 203, 2210-2221.	0.8	23
106	The transient HIV remission in the Mississippi baby: why is this good news?. Journal of the International AIDS Society, 2014, 17, 19859.	3.0	22
107	Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation. PLoS Pathogens, 2020, 16, e1008954.	4.7	22
108	Virologic failure is uncommon after treatment initiation during acute HIV infection. Aids, 2016, 30, 1943-1950.	2.2	21

#	Article	IF	Citations
109	Quality Monitoring of HIV-1-Infected and Uninfected Peripheral Blood Mononuclear Cell Samples in a Resource-Limited Setting. Vaccine Journal, 2010, 17, 910-918.	3.1	20
110	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS Computational Biology, 2020, 16, e1007626.	3.2	20
111	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology, 2021, 22, 1294-1305.	14.5	20
112	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. Journal of Immunological Methods, 2018, 462, 74-82.	1.4	19
113	The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes. PLoS Computational Biology, 2019, 15, e1007056.	3.2	19
114	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	3.4	19
115	Time to change the paradigm: limited condom and lubricant use among Nigerian men who have sex with men and transgender women despite availability and counseling. Annals of Epidemiology, 2019, 31, 11-19.e3.	1.9	18
116	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. Cell Host and Microbe, 2021, 29, 564-578.e9.	11.0	18
117	Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by Î±4Î²7 integrin. Virology, 2017, 508, 199-212.	2.4	18
118	HIV vaccine delayed boosting increases Env variable region 2â€“specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
119	Molecular Epidemiology of HIV Type 1 in Preparation for a Phase III Prime-Boost Vaccine Trial in Thailand and a New Approach to HIV Type 1 Genotyping. AIDS Research and Human Retroviruses, 2006, 22, 801-807.	1.1	17
120	HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels. Journal of Infectious Diseases, 2015, 211, 1574-1584.	4.0	17
121	Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. AIDS Research and Human Retroviruses, 2018, 34, 193-205.	1.1	17
122	Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand. Journal of the International AIDS Society, 2017, 20, 21652.	3.0	16
123	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight, 2018, 3, .	5.0	16
124	Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection. Cells, 2019, 8, 902.	4.1	15
125	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics, 2014, 66, 299-310.	2.4	14
126	Molecular epidemiology of a primarily MSM acute HIVâ€1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia. Journal of the International AIDS Society, 2018, 21, e25204.	3.0	14

#	Article	IF	Citations
127	Preferential Infection of Î±4Î²7+ Memory CD4+ T Cells During Early Acute Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases, 2020, 71, e735-e743.	5.8	14
128	RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 2020, 16, e1009101.	4.7	13
129	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 2019, 11, 607.	3.3	12
130	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. PLoS Pathogens, 2021, 17, e1009785.	4.7	12
131	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight, 2020, 5, .	5.0	12
132	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. Nature Communications, 2022, 13, .	12.8	12
133	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). AIDS Research and Human Retroviruses, 2014, 30, A33-A33.	1.1	11
134	Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight, 2017, 2, .	5.0	11
135	HyperPack: A Software Package for the Study of Levels, Contexts, and Patterns of APOBEC-Mediated Hypermutation in HIV. AIDS Research and Human Retroviruses, 2007, 23, 554-557.	1.1	9
136	Timing HIV infection with a simple and accurate population viral dynamics model. Journal of the Royal Society Interface, 2021, 18, 20210314.	3.4	8
137	Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 348-355.	2.1	7
138	Next-generation sequencing of HIV-1 single genome amplicons. Biomolecular Detection and Quantification, 2019, 17, 100080.	7.0	7
139	Nautilus: A Bioinformatics Package for the Analysis of HIV Type 1 Targeted Deep Sequencing Data. AIDS Research and Human Retroviruses, 2013, 29, 1361-1364.	1.1	6
140	Shot in the HAART: vaccine therapy for HIV. Lancet Infectious Diseases, The, 2014, 14, 259-260.	9.1	6
141	Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells, 2019, 8, 365.	4.1	6
142	Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection. Journal of Infectious Diseases, 2022, 225, 2167-2175.	4.0	6
143	Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. Journal of Virological Methods, 2014, 205, 7-16.	2.1	5
144	HIV prevalence and risk behavior among male and female adults screened for enrolment into a vaccine preparedness study in Maputo, Mozambique. PLoS ONE, 2019, 14, e0221682.	2.5	5

#	Article	IF	Citations
145	Sex and Urbanicity Contribute to Variation in Lymphocyte Distribution across Ugandan Populations. PLoS ONE, 2016, 11, e0146196.	2.5	5
146	HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS Pathogens, 2022, 18, e1010369.	4.7	5
147	HLA-Bâˆ—46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. Cell Host and Microbe, 2022, 30, 1173-1185.e8.	11.0	5
148	A de novo approach to inferring within-host fitness effects during untreated HIV-1 infection. PLoS Pathogens, 2020, 16, e1008171.	4.7	4
149	Factors influencing estimates of HIV-1 infection timing using BEAST. PLoS Computational Biology, 2021, 17, e1008537.	3.2	4
150	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	6.0	4
151	Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes.. Journal of Virological Methods, 2016, 230, 45-52.	2.1	3
152	Longitudinal Analysis of Peripheral and Colonic CD161+ CD4+ T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation. Viruses, 2020, 12, 1426.	3.3	3
153	Associations of gender identity with sexual behaviours, social stigma and sexually transmitted infections among adults who have sex with men in Abuja and Lagos, Nigeria. Journal of the International AIDS Society, 2022, 25, .	3.0	3
154	Evaluation of HIV-1 neutralizing and binding antibodies in maternal-infant transmission in Thailand. Virology, 2020, 548, 152-159.	2.4	2
155	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evolution, 2021, 7, veab057.	4.9	2
156	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Journal of Virology, 2021, 95, e0079721.	3.4	2
157	Preferential and persistent impact of acute HIV-1 infection on CD4⁺iNKT cells in colonic mucosa. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	2
158	HIV vaccine development: a new beginning. Expert Review of Vaccines, 2011, 10, 925-927.	4.4	1
159	Harnessing circulating microRNAs for early HIV diagnosis. EBioMedicine, 2019, 44, 18-19.	6.1	1
160	Dynamics of Human Immunodeficiency Virus-1 Genetic Diversification During Acute Infection. Open Forum Infectious Diseases, 2020, 7, ofaa429.	0.9	1
161	Feasibility and safety of research sigmoid colon biopsy in a cohort of Thai men who have sex with men with acute HIV-1. Journal of Virus Eradication, 2020, 6, 7-10.	0.5	1
162	Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study. PLoS ONE, 2021, 16, e0260126.	2.5	1

#	Article	IF	Citations
163	The Relationship between Stigma, Disclosure, and Adherence among Participants in the African Cohort Study. AIDS Research and Human Retroviruses, 2014, 30, A167-A167.	1.1	0
164	Vaccine Induced Seroreactivity in RV144 Vaccine Recipients in RV305, a Placebo Controlled Assessment of Late Boosts with ALVAC-HIV and AIDSVAX B/E. AIDS Research and Human Retroviruses, 2014, 30, A191-A191.	1.1	0
165	The doctor's dilemma and vaccine therapy for HIV. Lancet HIV,the, 2016, 3, e450-e451.	4.7	0
166	Accessories to SIV Control: T Cell Vaccination Shows Potential. EBioMedicine, 2017, 18, 17-18.	6.1	0
167	Feasibility and safety of research sigmoid colon biopsy in a cohort of Thai men who have sex with men with acute HIV-1. Journal of Virus Eradication, 2020, 6, 7-10.	0.5	0
168	HIV vaccine development: past, present and future. IDrugs: the Investigational Drugs Journal, 2010, 13, 852-6.	0.7	0
169	Title is missing!. , 2020, 16, e1007626.		0
170	Title is missing!. , 2020, 16, e1007626.		0
171	Title is missing!. , 2020, 16, e1007626.		0
172	Title is missing!. , 2020, 16, e1007626.		0
173	Susceptibility to HIV-1 Acquisition linked to Malaria Exposure: A Case-control Study. Clinical Infectious Diseases, 0, , .	5.8	0